prikaz prve stranice dokumenta Profiling Colorectal Cancer in the Landscape Personalized Testing—Advantages of Liquid Biopsy
  Preuzmi
PDF 1.04 MB
Znanstveni rad - Pregledni rad
Profiling Colorectal Cancer in the Landscape Personalized Testing—Advantages of Liquid Biopsy
International Journal of Molecular Sciences, 22 (2021), 9; 4327. https://doi.org/10.3390/ijms22094327
Verbanac, Donatella; Čeri, Andrea; Hlapčić, Iva; Shakibaei, Mehdi; Brockmueller, Aranka; Krušlin, Božo; Ljubičić, Neven; Baršić, Neven; Detel, Dijana; Batičić, Lara; Rumora, Lada; Somborac-Bačura, Anita; Štefanović, Mario; Ćelap, Ivana; Demirović, Alma; Petlevski, Roberta; Petrik, József; Grdić Rajković, Marija; Hulina-Tomašković, Andrea; Rako, Ivana; Saso, Luciano; Barišić, Karmela Više autora...

Institucijski repozitorij: Dr Med - digitalni repozitorij Medicinskog fakulteta Sveučilišta u Zagrebu

Citirajte ovaj rad

Verbanac, D., Čeri, A., Hlapčić, I., Shakibaei, M., Brockmueller, A., Krušlin, B. ... Barišić, K. (2021). Profiling Colorectal Cancer in the Landscape Personalized Testing—Advantages of Liquid Biopsy. International Journal of Molecular Sciences, 22. (9). doi: 10.3390/ijms22094327

Verbanac, Donatella, et al. "Profiling Colorectal Cancer in the Landscape Personalized Testing—Advantages of Liquid Biopsy." International Journal of Molecular Sciences, vol. 22, br. 9, 2021. https://doi.org/10.3390/ijms22094327

Verbanac, Donatella, Andrea Čeri, Iva Hlapčić, Mehdi Shakibaei, Aranka Brockmueller, Božo Krušlin, Neven Ljubičić, et al. "Profiling Colorectal Cancer in the Landscape Personalized Testing—Advantages of Liquid Biopsy." International Journal of Molecular Sciences 22, br. 9 (2021). https://doi.org/10.3390/ijms22094327

Verbanac, D., et al. (2021) 'Profiling Colorectal Cancer in the Landscape Personalized Testing—Advantages of Liquid Biopsy', International Journal of Molecular Sciences, 22(9). doi: 10.3390/ijms22094327

Verbanac D, Čeri A, Hlapčić I, Shakibaei M, Brockmueller A, Krušlin B, i sur.. Profiling Colorectal Cancer in the Landscape Personalized Testing—Advantages of Liquid Biopsy. International Journal of Molecular Sciences [Internet]. 21.04.2021. [pristupljeno 25.11.2024.];22(9). doi: 10.3390/ijms22094327

D. Verbanac, et al., "Profiling Colorectal Cancer in the Landscape Personalized Testing—Advantages of Liquid Biopsy", International Journal of Molecular Sciences, vol. 22, br. 9, Travanj 2021. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:556870. [Citirano: 25.11.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:556870
Podaci o radu
Naslov (engleski)Profiling Colorectal Cancer in the Landscape Personalized Testing—Advantages of Liquid Biopsy
AutorDonatella Verbanac
AutorAndrea Čeri
AutorIva Hlapčić
AutorMehdi Shakibaei
AutorAranka Brockmueller
AutorBožo Krušlin
AutorNeven Ljubičić
AutorNeven Baršić
AutorDijana Detel
AutorLara Batičić
AutorLada Rumora
AutorAnita Somborac-Bačura
AutorMario Štefanović
AutorIvana Ćelap
AutorAlma Demirović
AutorRoberta Petlevski
AutorJózsef Petrik
AutorMarija Grdić Rajković
AutorAndrea Hulina-Tomašković
AutorIvana Rako
AutorLuciano Saso
AutorKarmela Barišić
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA INTERNU MEDICINU)
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA PATOLOGIJU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Patologija
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Sažetak (engleski)
Drug-specific therapeutic approaches for colorectal cancer (CRC) have contributed to significant improvements in patient health. Nevertheless, there is still a great need to improve the personalization of treatments based on genetic and epigenetic tumor profiles to maximize the quality and efficacy while limiting cytotoxicity. Currently, CEA and CA 19-9 are the only validated blood biomarkers in clinical practice. For this reason, laboratories are trying to identify new specific prognostics and, more importantly, predictive biomarkers for CRC patient profiling. Thus, the unique landscape of personalized biomarker data should have a clinical impact on CRC treatment strategies and molecular genetic screening tests should become the standard method for diagnosing CRC. This review concentrates on recent molecular testing in CRC and discusses the potential modifications in CRC assay methodology with the upcoming clinical application of novel genomic approaches. While mechanisms for analyzing circulating tumor DNA have been proven too inaccurate, detecting and analyzing circulating tumor cells and protein analysis of exosomes represent more promising options. Blood liquid biopsy offers good prospects for the future if the results align with pathologists’ tissue analyses. Overall, early detection, accurate diagnosis and treatment monitoring for CRC with specific markers and targeted molecular testing may benefit many patients.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Pregledni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaInternational Journal of Molecular Sciences
Brojčani podacivol. 22, br. 9, 4327
e-ISSN1422-0067
DOIhttps://doi.org/10.3390/ijms22094327
URN:NBNurn:nbn:hr:105:556870
Datum objave publikacije2021-04-21
ProjektŠifra: IP-2019-04-4624
Naziv (hrvatski): Gensko, proteinsko i RNA profiliranje kolorektalnog karcinoma primjenom tekuće biopsije
Naziv (engleski): Genetic, Protein and RNA Profiling of Colorectal Cancer Using Liquid Biopsy
Kratica: CRCMolProfil
Voditelj: Karmela Barišić
Pravna nadležnost: Hrvatska
Financijer: HRZZ
Linija financiranja: IP
URL dokumentahttps://www.mdpi.com/1422-0067/22/9/4327
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2021-11-03 12:18:04